Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

MSL Talk

The Amazing History and Evolution of Medical Affairs in 32 Minutes

Jan 21, 202533 minVideo
ShareXLinkedInFacebookWhatsAppEmail

In this episode, Tom Caravela is joined by Ralph Rewers to explore the history and evolution of Medical Affairs. They discuss the origins and progression of Medical Affairs, including the significance of the first MSL deployment. The conversation highlights the relevance of a medical background for MSLs and factors contributing to their deployment amidst modern scientific complexities. Key milestones and the future impact of AI and technology on Medical Affairs are examined, along with the importance of internal stakeholder relationships and the rise of patient centricity. The episode also delves into KOL interaction dynamics and the future of Medical Affairs, concluding with Ralph's reflections on his career and retirement.

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Transcript

From the show.

0:03Welcome to MSL talk with Tom Caravella, a podcast specifically designed for MSL and all things field medical. Hey, guys. Welcome to the podcast. I am so excited to welcome Ralph Rouers, my dear friend and longtime colleague, to this podcast. Ralph is is a legend in medical affairs, so it's this conversation is gonna be a real

0:38treat. It's a long time coming, we've been planning this for a long time. We're gonna talk about the history and the evolution of medical affairs. Before I get into that, I just wanna recognize that we do have a sponsor, Momentum Events. Guys, you still have time to sign up for AI in Medical Affairs, which is a conference coming up in Philly, January 28th 29th. So go to AI in Medical Affairs, just type that into Google, it'll come right up or go to my LinkedIn page, you'll see it on there, you can register.

1:10If you use code MSL15, you get 15% off. So this is gonna be your last chance because the conference is in a couple weeks. So, check it out, and I hope to see you there. So Ralph, welcome to the podcast. Thank you, Tom. Appreciate it. And, thanks for the kind words, first of all, and I'm very honored to be on this. You said legend, but, Tom, you're a legend too. And and I mean that sincerely, not, not just from, you know, what we're gonna do here in the podcast, but also, you know, your ability to place people in positions and let them

1:43flourish, Tom. You you do an amazing you and your team do an amazing job, and so I'm I'm really honored to spend some time with you today. Thank you. Thank you. Thank you, my friend. And this topic is one that I've been wanting to do for a while because obviously we talk about MSL stuff, we talk about medical affairs stuff, but we've never really done an episode dedicated to the history and the evolution. So why don't we start with, what is the definition of medical affairs and how does it

2:14fit into the pharmaceutical industry? Yeah. It's a great question, Tom. And so I look at medical affairs as being unique. Unique in the aspect of, there's r and d, certainly. All companies will always have a research and development where they discover new compounds. They take them through clinical trials, and they bring them to launch. And then you get your commercial team on the other end of it, which is an organization that usually picks up the product about 6 months before launch, takes it through launch, and

2:46through its life cycle. Medical affairs sits in the middle. And so we have our feet in both areas, both on the r and d side and helping with development, helping with trials, helping with recruitment. And then on the other side, we take the product through launch and and through its life cycle, which also includes some additional studies, that we'll do to look at new indications. So it sits in a very unique aspect in that it's it has that foothold in both areas, and it's kind of that bridge. I call medical affairs a bridge between the 2 and taking the product from probably phase 1,

3:21phase 2 all the way through, until the end of life cycle. Awesome. And when, like, when did this happen? When was the origin of medical affairs in industry? Yeah. I really think, originally, medical affairs was usually, most companies called scientific affairs, and and they usually reported into research and development, because the research researchers needed someone, to work with thought leaders, to help to to develop the

3:53compounds, to develop new ideas, new indications. So really, it started in, I would say, in the late sixties, seventies, but but really the the organization started to flourish in the eighties nineties, and so, I'm not quite that old. I I wasn't I wasn't actually in medical court in 67. Let's put that out there. Well But, you know, that's really when it started to to to to really begin. Yeah. And and this next question is is a very common trivia question in medical affairs.

4:28So I want everybody to pay attention because you might actually get this at a conference or some kind of training in the future. But when was the first ever MSL deployed as far as you know? So as far as I know, I don't know the name of the person. Gotta be honest. And and, yes, I was alive, but still pretty pretty much in grade school. But the the first MSL was deployed by the Upjohn company, and that was 1967. So as far as records go, that's what's quoted, and and I tend to believe that that quite a

5:03bit. And that's what I've heard. I've heard the same thing. I think that that's that's kinda common well, it's kind of the common, I guess, answer to that question. Coincidentally, I was born in 1960 7. So I'm as old as as the first MSL. Go figure. Yeah. The other thing, Tom, really interesting as an addition is, you know, I graduated, from Purdue University in in pharmacy school in 1980, And half of my half of my class, because we were

5:38very close to Eli Lilly there in Indiana, half of my class actually were recruited to be sales representatives. And so I do know that Eli Lilly, Upjohn, and Merck at that time in in in the early eighties deployed all of their sales reps were pharmacists. So every one of them had a pharmacy background. So you can see how that's evolved over time too. So back then, in the eighties, most of sales reps had medical backgrounds, and now that's

6:08evolved to more of a a commercial presence of people without medical backgrounds. And I do think that really kinda set the tone for building a medical affairs department and MSLs to complement because there were less, pharmacists employed in in the sales department. So I think that's another piece that actually kind of evolved over time. Yeah. That's con that's interesting. It's kind of a telltale sign of how things you know, part of that evolution. When I was a rep a long time ago, there weren't this is back in the eighties nineties time

6:44frame. There were not a lot of MSLs that I recall. We had actually we had no MSLs in my company, but we had a speakers bureau. So it was almost like a rent to MSL. Like, you you actually had to bring an expert in to do presentations and and that sort of thing. So, so things have really exploded over the years. But let me ask you, what would you say, getting back to the origin of the MSL, what were what

7:14were the key factors or what were the needs that would have led to these companies putting out MSLs? Yeah. So I I believe, Tom, I I really think and and I was there, you know, in the I started well, I started in clinical practice in 1980. That's been 14 years in practice and actually would have a MSL like person call on me in the hospital. And then subsequently, I I started in in 1994. But really, the key factors, were while the representatives had the ability to engage the

7:49docs and build trust and build relationships, there were a lot of deep scientific questions and questions that were potentially outside the label that a representative couldn't really answer. And so when you started to talk about deep science, when you started to talk about even some very early pharmacoeconomic data, how do we balance the cost of a medication, and how can we look at broader sense and and, you know, things like, showing the value of medicines,

8:20and having those deep scientific conversations. That's where I think the MSLs and and field medical could, could flourish. And then also a lot of people had ideas, you know, I know the drug is indicated here, but I think it also can be effective here in this other indication. And so who would work with them? Who'd be out in the field to kinda help them? And that certainly was some of the factors that, led to, an increase in medical affairs as well as field medical, the MSLs. Got you. Yeah.

8:51We've seen such a we've seen this take off, the MSL role and medical affairs. Can you talk about the evolution and how it went from those days to how it's kind of evolved into this present day. Yeah, Tom. I think, you know, really, the the the need is there and the needs here today even for, that deep scientific knowledge and understanding. So as you know today, there's so much science out there.

9:24There is no way possible that anyone, even a thought leader who spends their entire life in one area, can possibly keep up with data. And so here's where a medical department can actually be able to have those deep scientific discussions and come up with other ways in how to solve, you know, solve these issues. I think the, the the the ability to have these long scientific discussions. I mean, I remember the day when we could sit down for 30, 40, 50 minutes and and and and

9:58really kinda digest the data and kinda help people along. We'll talk about it later. That's that's actually changed quite a bit as you might imagine. But there there really was a need for, for that. And then then also, you know, we we we we look at different different factors from, studies. We look at the fact of looking beyond the value and things like that. So I do think that there there really are things that that really have evolved. And then medical has a presence, medical has a voice, and and I'd be remiss if I didn't say

10:32that in medical affairs, we definitely are patient focused. There's there's a lot of people that talk about, you know, different things, but keeping up that patient focus is essential, for us to be successful. Love it. Love it. And what about as you look through the past, were there any milestones or turning points over the course of time? Yeah. Yeah. There there was. I mean, I remember the days when I first started. No one really kinda knew what medical affairs was.

11:04You know, there's always a commercial organization, a marketing organization, and there was always that research. But, you know, they're like like, who are you guys? What do you do? And so, we had to do a lot of education about the potential of what medical affairs could do. Now I believe we're an equal partner. So when we start to launch products now, when we start to do early things, you always have r and d, medical affairs, and commercial in, and they work together because we all have different points of view. And so that's really what I see the evolution.

11:36It's the seat at the table that we we all have today now. But I will tell you there were some milestones, and I'll go back again when I first started in the nineties. The representatives, there was something called the Waxman Act, and and the representatives at that point could take a a paper that was off label. There were in in you know, there's a scientific data that was outside the label. They would be able to come to the doctor. They would give in a nice plastic folder, they would hand this to the doctor and say, here's

12:10some interesting information. I can't talk about it, but I will have, this MSL person, this field medical person come back and talk to you about it if you're interested. And so those were the very, very early days, of that. And then what happened is, you know, there just was, a lot of there was a thing called MedWatch, that the FDA had implemented in the in in the in the in the nineties, where there was a very high focus on not promoting off label.

12:43So remember, when I talked about this, this was unsolicited. You'd have to ask a question and and and and do that, and that's the way things are today. But but but companies kinda took some liberties and started to promote off label, and then the government said, no. This is not right. And there were many suits that were brought against companies. And and, actually, a $1,000,000,000, suits through, you know, through through the government, and and, and the OIG department and and and and pharma.

13:15And so what happened was there was a a retraction. So so we retracted and no one could talk about things off label. People there are compliance departments that were built up. And for a while, the MSO and and field medical medical affairs functions were under big scrutiny, making sure that we were doing all the right things. Now that's right, Tom. It it's absolutely right. Sometimes you you get some momentum and you need to be, you know, reined in and brought back. But what I've seen recently, is again an evolution of the government saying, you know

13:51what? There are a lot of products that are out there that they don't have a labeled indication, but there needs to be discussions about this. And we need to help patients again. And so there's just something recently the FDA has granted guidance. It's called s SIUU, and that's scientific information on unlabeled uses. And the government, the FDA has now said that you can, in certain instances, if you have something that's been in a peer reviewed journal, you can discuss it. The medical department can discuss it proactively with the physician.

14:24And so you see how this has kinda come full circle. So, you know, this waxes and wanes, but but, you know, it's it's you know, at the end of the day, what we want is we want to have the scientific information given to the provider so that they can help the patient at the right time. And so I think all of this is kinda coming to fruition and, you know, it it it kinda waxes and wanes over these years. Yeah. Yeah. And you I keep hearing you talk about science, deep science, and so when we look at the the

14:59rise of science and technology and advancement, How has that elevated or played a part in medical affairs over the years? Yeah. It's it's really remarkable. When I think back about all the things that that have transpired over these 30 years, the science is so complex, Tom. Mhmm. It's it's it's not easily describable. I remember I launched Lipitor, and all you had to do is say, hey. It lowered LDL, the bad cholesterol, and it raised good cholesterol, and that was about it.

15:35You know, I I've been in the oncology world for about the last 13 to 15 years. The evolution of biomarkers, the evolution of of of targeted therapy, it is so complex, and especially for the routine community doc, for the routine, provider, the general oncologist. It is so difficult for them to keep up. They need a medical person to augment the commercial person to be able to really talk and

16:06make sure that the the, the the agents are used appropriately, for the right patient at the right time. And so, you know, we have a lot of guidance documents. We have a lot of guidelines that are out there, but medical really needs to be able to simplify these complex areas and complex terms so that prescribers can really get the information they need. So it it really has evolved. And I think what you just said, there should be a collective sigh of relief after hearing you

16:39say that because I think there's a lot of people, and I know because I talk to them, that are worried about artificial intelligence and machine learning. And is there going to come a time where a machine can do the job of an MSL, where a KOL just has to go in front of a kiosk and just ask it questions and then get the answers, and then, I don't need the MSL. What you just said proves that can the complexity of science in this day and age makes it so vital to have a human in that seat, or am I over exaggerating that?

17:15Oh, you're not over exaggerating at all, Tom. I get the same question too. You know, I've I've gotten this question for the last couple of years. The one thing we have to remember is, first of all, we're all human. We need a human interaction. We need to have, like, we're having right here and that right now. We need to have a dialogue back and forth. And while AI will get very good at facts, so the it it will be able to certainly augment and help. I look at AI being able to spread information, help information.

17:49Most companies, you know, the the the, ratio of a representative to an MSL is sometimes around 10 to 1, you know, 10 reps to 1 MSL. In oncology, it's a little smaller, maybe 4 reps to 1 MSL. There's never going to be enough MSLs to cover every doc out there. It just and and let's not even talk about just just, physicians, but PAs, nurse practitioners, those extenders, those important people who diagnose and treat, they need to have that

18:22information. So we're never going to get to a point. AI will help. It's going to help us, but it will never take the place of a human because the human can think and and and and we can also alter our plan. You know, when we talked about what we're gonna talk about today, we're gonna go off on a lot of tangents. Right? AI cannot do that, but humans can. We have the thinking process. We have the knowledge, and I'll argue most of us, at least in the MSL world, have clinical experience.

18:52And so I can still rely on that clinical experience I had for 14 years, how many years ago, and you need that human element, Tom. It'll never go away. Yeah. I I think that's I I honestly think that that's such an important piece of information to share with the medical affairs community right now because I think a lot of people are are concerned about that. But as you said, it's it's not just I don't think it's just the complexity of the science. I think it's the way the health care industry has evolved as well.

19:24Like you said, there's nurse practitioners and PAs, and there's just so much that's involved in it now, and they need the help of field medical. So I love it. Let me ask you this. As we look at the we talk about relationships with internal stakeholders. How has it how how has that evolved over the course of time when we look at the relationship between medical affairs and r and d, marketing, obviously, you know, commercial counterparts?

19:59How much has that changed? That's changed, dramatically, actually, over the years, and and I alluded to it a little earlier, but let's dive in a little bit deeper. I think at one point, people just wondered, well, what what do you guys do in medical affairs? But now, there's not a company out there, eve even very small startups. One of the first departments that will be, started will be medical affairs. And and so, even even early in in the development of compounds, you need a a a

20:32medical person there to guide, to look at the landscape, the environment, what are the competitors that are out there. Because remember, it's not just about your product. It's about the competitors, and I can remember doing some clinical trials take, you know, 3 to 4 years to complete. Well, a lot happens in that 3 to 4 years. New products come on the market. New tests come out, diagnostic tests, biomarkers. The science is constantly evolving. And so what I see now, and I'm thrilled to see it, is everybody are equal partners.

21:06And we all have our areas of expertise and going back to where we started here about medical affairs, having their feet both in the research end of it, as well as the commercial end of it and may ensuring that that everyone uses the product safely and effectively, you know, that's really, dramatically changed. And and I'm glad to see it because I think all of us working together. You know, when you have 3 minds working on one project, it's always better than 1. And so I think everybody has their areas of focus and strengths, and we all the the key

21:39element is everybody has to respect each other's opinions, Tom, and that's what I've seen over the last few years. I've had great partners, where I've been in the last last few companies, and and that's really where it where where it's invaluable. Yep. Yep. What about the pay on the patient's side? Would you say the increased need for patient centricity, how has that influenced medical affairs and MSLs? It's it's it's really changed a lot.

22:09So first of all, we get patients involved when we're designing studies because we always think about science, you know, get the science. Here's this. But patients will say, well, you know what? I can't take this product. You know, we what what about if we have some side effects and I can't, you know, are are there different ways to deliver the compound? You think about this. We've got incredible technology where we've we have auto injectors that auto inject the medicine, you know, in itself. We we have different ways to deploy, and we need a patient.

22:41And so we start with patients. We use we work a lot with patient advocacy groups, and patient advocates that help us design trials. So that's on the early end. On the later end, they also help us to to to kind of look at, how of what we call real war world evidence. And so the the the patients give us ideas about how how this can be used in in in the real world because anytime we do a clinical trial, it's an artificial environment.

23:15You know, they're in a clinical trial and they're getting placebo or they're getting active control. That's not really real life, but we we start to look at this and we start to look at, that that ability to to have real world evidence and do that. And and and then then certainly there's affordability of medicines and and how we do that. So at the end of the day, Tom, we still need to have the patient. We we say this a lot, but it's truly meaningful. The patient is our North Star. We never should do anything without the patient in mind whenever we do anything, whether it's

23:50develop trials or getting a product out to market. So patient centricity is it's always been there, but it's even more important now because of the complexity of the medicines that we have. Yeah. And I'm curious. I'm thinking back to the, you know, KOLs and HCPs, and how different is KOL interaction now versus back in the day? Yeah. Yeah. It's a it's a great question.

24:21And and, you know, so this is the only time I'll say the pandemic had a positive influence. This is the only thing I could think that's good about the pandemic, and that is our our our thought leaders, our HCLs, our our our our practitioners learned how to use Zoom. Yeah. Okay. So they never used to do that before. I had no idea. I just come into the office. I I don't know how to work this stuff. Right. And so they they learn that. And and by doing that, we could extend our reach.

24:51Okay? So we can send our reach and we could reach out. We're used to we'd have MSLs drive 3 hours to a small little town, have a half an hour meeting, and drive 3 hours back. Now we just pull up a Zoom call, and and we can get a lot more done still having that that dialogue. However, our attention spans have shrunk, Tom. So the old days of me coming with my computer and setting up the projector and going through 30 to 40 slides, that's over, Tom. So Yeah.

25:22People are still doing that. That's gonna be very difficult to hold people's attention spans. And so now we have to develop to, techniques. We need to do a lot of training on this, but how do you tell that complex story, that complex scientific story in 5 minutes? And how can we make it stick? And there's a lot of bioscience around this, Tom, and and and and and there's so I see this as the future. So we have to be and and everybody has their their phone with them.

25:53Right? And you know what attention spans are on phone. You know, if you don't get that information 3 to 4 minutes, forget it. I'm gone. And so that's really has evolved the way we discuss science and how we can still have impact. So that's, I think, changed dramatically, but but, you know, there's there's still that opportunity for for that live interaction. Yeah. You mentioned the future. What what do you see happening in the future? Now that we've talked about the history and the evolution, like, what what's next for medical?

26:25So I'll I'll start with saying what's gonna stay the same. Okay? And then get what's next. But what's gonna stay the same is you still need that patient focus. If we ever lose the fact that we're we are not representing a product, we're representing a patient and and and how they can get better on our medicines. I still think live interactions will be there, Tom, forever. Yeah. It's just gonna be very much changed. The other thing that won't change is trust.

26:56We talk a lot about what we do, but if we don't develop trust with the people that we interact with and engage with, we'll lose that ability to to to to really engage. But what I really think will will change is some of the things we talked about, AI. I think AI is gonna help us a lot, Tom. It's gonna help us to just navigate through all the morass of all the science. So I think AI is gonna be there. I think, us changing our focus to short bites of information and getting information to

27:31people. And then also figuring out ways because, you know, we need to figure out a way when it's 3 o'clock in the morning and somebody needs an answer, how can we still get a interaction that's gonna be meaningful to someone because they got a patient in front of them? So those things will change. They'll evolve. But, you know, I always believe in in that trust and that relationship. And I think we'll always need MSLs. We just will need to evolve the way we do our job, Tom.

28:05And if and if we have a it's sort it's sort of Darwinian. If you think about it, you know, it's it's it's it's the only way that you're gonna survive is is you're gonna survive or die. And I do think we can use these tools, these trainings, all of this to continue with with what we do. Yeah. Well, it's funny. I I've been in the industry for a long time, not as long as you, but I've been in for a pretty long time. And going back in the 25 years I've been doing this, you know, I go to a lot of conferences,

28:36and I feel like we're still talking about the same stuff. So what we were talking about, the value of field medical and the and metrics. And just I just feel like a lot of the topics have continued to stay relevant over the course of many, many years. And now there's new things. There's omnichannel. There's AI. So there's a lot of new things. So where do you see like, what are we gonna be talking I mean, you just mentioned a couple of

29:09things, but, like, do you think we're still gonna be talking about the same stuff in 5 or 10 years, or do you think that there's gonna be drastic changes? I I think for the most part, we're gonna talk a lot about the same things. Let's talk about metrics, which is one of my it's a topic I've, you know, I've talked about for 30 years. But but but if you if you peel that back, why are people asking you for metrics? Well, they wanna make sure you're showing value to the company. I mean, they're paying people a lot of money to get out there, engage with people.

29:41Yeah. So, yes, there's always gonna be a way to look at metrics. Now can we get better at measuring that? Can we look at impact? Yeah. We can. And and, you know, there's there's tools out there now, Tom, that I think a lot of companies are looking at and in in how, you know, we we talk a lot about things like sentiment. How do people change their mindset, their their thoughts about new entities, new products, new indications, you know, the ability to diagnose quicker.

30:12Yeah. Those will change, but we've gotta get better ways to to measure that. And so those are ways we've never you know, we we tend to I always say in metrics, we tend to to track what we can track, and we can track an interaction. And, yeah, that's that's a but it's a pseudo, you know, measurement. I do think we'll come up with some abilities through innovations in in technology to show the impact that we're having. So so for instance, if we could diagnose people earlier, if we can treat them earlier, if we

30:46can even prevent disease from ever occurring, I think those are the things we need to, to really concentrate. And that and that technology will evolve, Tom, and that's gonna help us, to to show those those types of measurements and the impact that we have. We know we have impact. It's just hard to show it sometimes, and I think we're gonna evolve in that area. Ralph, you're the best. Appreciate it, brother. This I was so excited to have you on, and and, of course, you you crushed it. You did not disappoint. So thank you so much. How's retirement treating you?

31:17Retirement's treating me very well, Tom. There's a little story here. I'm sitting in a study room in Pima County. I'm sitting in Arizona warming up for a couple of months in my RV, but I still get this great opportunity to talk to you and engage. So it's kind of the best of both worlds. So retirement's great. I was a little worried that I wasn't gonna have anything to do, but, hey, Tom. It's, it's all great. When you're as good as Ralph Brewers, you'll always have stuff to do because everybody's gonna wanna have a piece of you. I know I'm one of those.

31:48So you just made my day, and I'm just grateful that I've had the opportunity today to share you with my audience. So thank you again. And everybody that's listening right now, thank you for your support. Please share this with others because I think it's just it's such great information if you're interested in medical affairs. So as always, we'll see you next time. Thanks, Ralph. Take care. Take care, Tom. Thanks a lot.

32:21Thank you so much for listening to the show, and if you enjoyed it, please subscribe so that you don't miss an episode in the future, and feel free to leave a rating or a review or a comment. Thanks again, and we look forward to seeing you soon.

Open the transcript file

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. The Wrong Voices: How Bad Mentors Can Ruin Your Career

    Nov 17, 202628 minVideo

    What qualifies someone to influence your future? Tom Caravela explains why career guidance should be filtered through relevant experience, current knowledge, credibility, and objectivity. He examines the risks of...

    Listen to the audio

    Credit the people on this episode

  2. Hidden Secret to Career Happiness and Longevity

    Nov 3, 202635 minVideo

    What turns an industry contact into a long-term ally? In this episode, Tom Caravela and Ed Doherty look beyond transactional networking to the genuine friendships that can shape a career in medical affairs. They discuss...

    Listen to the audio

    Credit the people on this episode

  3. How to AI-Proof Your Career: The 4 Pillars of Career Success

    Oct 20, 202623 minVideo

    Becoming undeniable is Tom Caravela’s answer to building career security in the age of AI. He breaks down four pillars you can control: skills, experience, relationships, and brand. Tom explains how continuous learning...

    Listen to the audio

    Credit the people on this episode

  4. How Medical Affairs Influences Decisions that Matter

    Oct 13, 202638 minVideo

    What happens after an MSL submits an insight? In this episode, Tom Caravela and Cameron Tew examine how field observations create value only when organizations decide what to do next. They discuss shared definitions,...

    Listen to the audio

    Credit the people on this episode

  5. Stop Being Your Own Worst Enemy

    Sep 29, 202619 minVideo

    In this episode, Tom Caravela discusses common mindset traps that can hold Medical Science Liaisons and aspiring MSLs back. He covers how to move past worst-case thinking, overanalysis, concern about others’ opinions,...

    Listen to the audio

    Credit the people on this episode